

References

I-65

1. Adkins D, Ley J, Trinkaus K, et al. A phase 2 trial of induction nab-paclitaxel and cetuximab given with cisplatin and 5-fluorouracil followed by concurrent cisplatin and radiation for locally advanced squamous cell carcinoma of the head and neck. *Cancer*. 2013;119(4):766-773.
2. Alberts DS, et al. Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study. *Gyn Onc*. 2012;127:451-455.
3. Chen J, Gu W, Xu Z, et al. Nanotechnology in the management of cervical cancer. *Reviews In Medical Virology*. March 2015;25 Suppl 1:72-83.
4. Hoy S. Albumin-Bound Paclitaxel: A Review of Its Use for the First-Line Combination Treatment of Metastatic Pancreatic Cancer. *Drugs*. October 2014;74(15):1757-1768.
5. Kottschade LA, Suman VJ, Amatruda T 3rd, et al. A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : A North Central Cancer Treatment Group Study, N057E(1). *Cancer*. 2011;117(8):1704-1710.
6. Ko YJ, Canil,C., Mukherjee SD, et al. Nanoparticle albumin-bound paclitaxel for secondline treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study. *Lancet Oncol* 2013; 14:769-76.
7. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. *Am J Clin Oncol*.1982;5(6):649-655.
8. National Comprehensive Cancer Network (NCCN). *NCCN Drugs & Biologics Compendium*. Paclitaxel, albumin bound. [NCCN Web site] 2017.
9. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology – Bladder Cancer. V2.2017. [NCCN Web site]. February 15, 2017.
10. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology – Breast Cancer. V2.2017. [NCCN Web site]. April 6, 2017.
11. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology – Cervical Cancer. V1.2017. [NCCN Web site]. October 10, 2016.
12. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology – Melanoma. V1.2017. [NCCN Web site]. November 10, 2016.
13. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology – Non-Small Cell Lung Cancer. V5.2017. [NCCN Web site]. March 16, 2017.
14. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology – Ovarian Cancer. V1.2017. [NCCN Web site]. April 12, 2017.
15. National Comprehensive Cancer Network (NCCN). *NCCN Clinical Practice Guidelines in Oncology - Pancreatic Adenocarcinoma*.V1.2017. [NCCN Web site]. February 24, 2017.
16. Socinski MA, Bondarenko I, Karaseva NA, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients

with advanced non-small-cell lung cancer: Final results of a phase III trial. *J Clin Oncol*. 2012;30(17):2055-2062.

17. Socinski M, Langer C, Renschler M, et al. Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer. *Annals Of Oncology: Official Journal Of The European Society For Medical Oncology / ESMO*. February 2013;24(2):314-321.